Aspire Biopharma Holdings (ASBP) Free Cash Flow Growth (3y) (2024 - 2026)
Aspire Biopharma Holdings (ASBP) Free Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 31.42% |
| 10 | Aspire Biopharma Holdings | 1.10 Mn | -724,996.75 | 5,750.00 | -155.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -155.53% |
| Dec 31, 2025 | -195.74% |
| Sep 30, 2025 | -187.14% |
| Jun 30, 2025 | -209.75% |
| Mar 31, 2025 | -10.79% |
| Dec 31, 2024 | 173.85% |